Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort.
| Title: | Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. |
|---|---|
| Authors: | Quaranta MG; Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.; Ferrigno L; Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.; Monti M; Center for Systemic Manifestations of Hepatitis Viruses (MaSVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.; Filomia R; Division of Clinical and Molecular Hepatology, University Hospital of Messina, Messina, Italy.; Biliotti E; Department of Clinical Medicine, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.; Iannone A; Department of Emergency and Organ Transplantation, Gastroenterology Unit, University of Bari, Bari, Italy.; Migliorino G; Division of Infectious Diseases, San Gerardo Hospital, Monza, Italy.; Coco B; Hepatology and Liver Physiopathology Laboratory and Internal Medicine, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.; Morisco F; Gastroenterology and Hepatology Unit, Federico II University Hospital, Naples, Italy.; Vinci M; Department of Hepatology and Gastroenterology, Niguarda Hospital, Milan, Italy.; D'Ambrosio R; Gastroenterology and Hepatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Chemello L; Department of Medicine, University Hospital of Padua, Padua, Italy.; Massari M; Infectious Diseases, Azienda Unità Sanitaria Locale, IRCCS di Reggio Emilia, Reggio Emilia, Italy.; Ieluzzi D; USD Liver Unit, University Hospital of Verona, Verona, Italy.; Russo FP; Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.; Blanc P; Infectious Disease Unit, Santa Maria Annunziata Hospital, Florence, Italy.; Verucchi G; Department of Medical and Surgical Sciences, Infectious Disease Unit, University Hospital S.Orsola-Malpighi, Bologna, Italy.; Puoti M; Department of Infectious Disease, Niguarda Hospital, Milan, Italy.; Rumi MG; Hepatology Unit, San Giuseppe Hospital, University of Milan, Milan, Italy.; Barbaro F; Infectious and Tropical Diseases Unit, Azienda Ospedaliera di Padova, Padua, Italy.; Santantonio TA; Infectious Diseases, Ospedali Riuniti, Foggia, Italy.; Federico A; Department of Hepato-Gastroenterology, University of Campania 'Luigi Vanvitelli', Naples, Italy.; Chessa L; Liver Unit, University Hospital, Monserrato, Cagliari, Italy.; Gentile I; Infectious Disease Unit, Federico II University Hospital, Naples, Italy.; Zuin M; Gastroenterology and Hepatology Unit, San Paolo Hospital, University of Milan, Milan, Italy.; Parruti G; Infectious Disease Unit, Spirito Santo General Hospital, Pescara, Italy.; Morsica G; Department of Infectious Diseases, San Raffaele Hospital, Milan, Italy.; Kondili LA; Center for Global Health, Istituto Superiore di Sanità, Rome, Italy. loreta.kondili@iss.it. |
| Corporate Authors: | PITER Collaborating Group |
| Source: | Hepatology international [Hepatol Int] 2020 May; Vol. 14 (3), pp. 362-372. Date of Electronic Publication: 2020 Apr 11. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 101304009 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1936-0541 (Electronic) Linking ISSN: 19360533 NLM ISO Abbreviation: Hepatol Int Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: New York, NY : Springer |
| MeSH Terms: | Carcinoma, Hepatocellular*/pathology ; Carcinoma, Hepatocellular*/physiopathology ; Carcinoma, Hepatocellular*/virology ; HIV Infections*/diagnosis ; HIV Infections*/drug therapy ; HIV Infections*/epidemiology ; Hepatitis C, Chronic*/diagnosis ; Hepatitis C, Chronic*/drug therapy ; Hepatitis C, Chronic*/epidemiology ; Liver*/physiopathology ; Liver*/virology ; Liver Cirrhosis*/diagnosis ; Liver Cirrhosis*/physiopathology ; Liver Cirrhosis*/virology ; Liver Neoplasms*/pathology ; Liver Neoplasms*/physiopathology ; Liver Neoplasms*/virology; Antiviral Agents/*therapeutic use; Italy/epidemiology ; Coinfection ; Disease Progression ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Prognosis ; Sustained Virologic Response |
| Abstract: | Background: Liver disease progression after Hepatitis C Virus (HCV) eradication following direct-acting antiviral (DAA) treatment in the real-life setting according to Human Immunodeficiency Virus (HIV) coinfection was evaluated.; Methods: Patients consecutively enrolled in PITER between April 2014 and June 2019 and with at least 12-weeks follow-up following treatment were analysed. Cox regression analysis were used to evaluate HIV coinfection and factors independently associated with liver disease outcomes following viral eradication in DAA treated patients with pre-treatment liver cirrhosis.; Results: 93 HIV/HCV coinfected and 1109 HCV monoinfected patients were evaluated during a median follow-up of 26.7 (range 6-44.6) and 24.6 (range 6.8-47.3) months, respectively. No difference in the cumulative HCC incidence and hepatic decompensation was observed between coinfected and monoinfected patients. Age (Hazard Ratio [HR] = 1.08; 95% CI 1.04-1.13), male sex (HR = 2.76; 95% CI 1.28-5.96), lower albumin levels (HR = 3.94; 95% CI 1.81-8.58), genotype 3 (HR = 5.05; 95% CI 1.75-14.57) and serum anti-HBc positivity (HR = 1.99, 95% CI 1.01-3.95) were independently associated with HCC incidence. Older age (HR = 1.03; 95% CI 1.00-1.07), male sex (HR = 2.13; 95% CI 1.06-4.26) and lower albumin levels (HR = 3.75; 95% CI 1.89-7.46) were independently associated with the appearance of a decompensating event after viral eradication.; Conclusion: Different demographic, clinical and genotype distribution between HIV coinfected vs those monoinfected, was observed in a representative cohort of HCV infected patients in Italy. Once liver cirrhosis is established the disease progression is decreased, but still persists regardless of viral eradication in both coinfected and monoinfected patients. In patients with cirrhosis, HIV coinfection was not associated with a higher probability of liver complications, after viral eradication. |
| References: | Clin Infect Dis. 2016 Nov 1;63(9):1160-1167. (PMID: 27506682); Gastroenterology. 2018 Aug;155(2):411-421.e4. (PMID: 29655836); Hepatol Int. 2019 Jan;13(1):66-74. (PMID: 30523552); J Hepatol. 2018 Aug;69(2):345-352. (PMID: 29551707); Am J Gastroenterol. 2015 Aug;110(8):1169-77; quiz 1178. (PMID: 26215529); Clin Infect Dis. 2013 Jan;56(1):143-50. (PMID: 22955438); J Hepatol. 2017 Mar;66(3):485-493. (PMID: 27780714); PLoS One. 2017 May 17;12(5):e0177402. (PMID: 28520749); Expert Opin Drug Saf. 2019 Jul;18(7):603-610. (PMID: 31067134); N Engl J Med. 2014 Jan 16;370(3):211-21. (PMID: 24428467); Curr Opin Gastroenterol. 2017 May;33(3):120-127. (PMID: 28234770); Clin Infect Dis. 2013 Nov;57(10):1401-8. (PMID: 23946224); J Hepatol. 1998 Nov;29(5):701-6. (PMID: 9833906); N Engl J Med. 2014 Apr 17;370(16):1483-93. (PMID: 24725238); PLoS One. 2017 Oct 4;12(10):e0185728. (PMID: 28977040); AIDS. 2019 Jun 1;33(7):1167-1174. (PMID: 30845068); Clin Infect Dis. 2016 Nov 15;63(10):1320-1324. (PMID: 27535952); J Hepatol. 2016 Oct;65(4):734-740. (PMID: 27288051); Lancet. 2019 Apr 6;393(10179):1453-1464. (PMID: 30765123); Lancet Infect Dis. 2016 Jul;16(7):797-808. (PMID: 26922272); Hepatology. 2005 Jan;41(1):48-54. (PMID: 15690481); J Hepatol. 2017 Jul;67(1):23-31. (PMID: 28235612); Hepatology. 1997 Oct;26(4):1006-11. (PMID: 9328327); Dig Liver Dis. 2015 Sep;47(9):741-3. (PMID: 26138800); PLoS One. 2016 Mar 08;11(3):e0150176. (PMID: 26954020); Hepatol Int. 2019 May;13(3):293-301. (PMID: 30820753); PLoS One. 2014 Jul 28;9(7):e103345. (PMID: 25068274); Dig Liver Dis. 2019 Feb;51(2):310-317. (PMID: 30473220) |
| Grant Information: | RF-2016-02364053 Ministero della Salute |
| Contributed Indexing: | Keywords: Advanced liver disease; Cirrhosis; Clinical outcomes; Coinfection; Direct-acting antivirals; Hepatitis C virus; Hepatocellular carcinoma; Human immunodeficiency virus; Real-life cohort; Sustained virological response; Viral eradication |
| Substance Nomenclature: | 0 (Antiviral Agents) |
| Entry Date(s): | Date Created: 20200413 Date Completed: 20210416 Latest Revision: 20210416 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC7220859 |
| DOI: | 10.1007/s12072-020-10034-0 |
| PMID: | 32279177 |
| Database: | MEDLINE |
Journal Article